Literature DB >> 28944430

Polymorphism of Matrix Metalloproteinases Genes MMP1, MMP2, MMP3, and MMP7 and the Risk of Varicose Veins of Lower Extremities.

A S Shadrina1, M A Smetanina2, K S Sevost'yanova2, A I Shevela2, E I Seliverstov3, E A Zakharova3, E N Voronina2, E A Ilyukhin4, I A Zolotukhin3, A I Kirienko3, M L Filipenko2.   

Abstract

We studied the effects of single nucleotide polymorphisms in the promoter regions of matrix metalloproteinase genes rs1799750 (-1607dupG) MMP1, rs243865 (C-1306T) MMP2, rs3025058 (-1171dupA) MMP3, and rs11568818 (A-181G) MMP7 on the risk of varicose vein of the lower extremities in ethnical Russians, residents of the Russian Federation. We genotyped 536 patients with this pathology and 273 healthy participants without history of chronic venous disease. Association was examined using logistic regression analysis. None of the studied polymorphisms showed statistically significant association with the risk of varicose veins of the lower extremities. Our results provide evidence that these polymorphisms are not involved in the pathogenesis of varicose veins and cannot serve as markers of predisposition to this pathology.

Entities:  

Keywords:  gene polymorphism; lower extremity varicose vein disease; matrix metalloproteinases

Mesh:

Substances:

Year:  2017        PMID: 28944430     DOI: 10.1007/s10517-017-3871-2

Source DB:  PubMed          Journal:  Bull Exp Biol Med        ISSN: 0007-4888            Impact factor:   0.804


  2 in total

1.  Efficacy and safety of polidocanol in the treatment of varicose veins of lower extremities: A protocol for systematic review and meta-analysis.

Authors:  Nan Li; Junhai Li; Mei Huang; Xiujun Zhang
Journal:  Medicine (Baltimore)       Date:  2021-02-26       Impact factor: 1.817

2.  Delphi case: Sharing of clinical experiences for improvement in the treatment of chronic venous disease.

Authors:  Giuseppe Camporese; Teresa Lucia Aloi; Angelo Santoliquido
Journal:  Front Cardiovasc Med       Date:  2022-07-18
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.